Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMRNNASDAQ:DYNNASDAQ:TBPHNASDAQ:TYRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$0.86-2.3%$0.99$0.65▼$1.49$353.22M1.981.97 million shs713,302 shsDYNDyne Therapeutics$23.70-5.1%$26.06$6.40▼$30.27$2.04B0.951.96 million shs705,850 shsTBPHTheravance Biopharma$9.14-0.3%$9.06$8.21▼$11.98$443.84M0.36382,401 shs387,247 shsTYRATyra Biosciences$15.11-5.6%$17.53$10.38▼$20.67$793.58M1.12130,877 shs137,545 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.53%-4.20%+4.11%-30.27%-31.36%DYNDyne Therapeutics-1.81%+0.64%-4.14%+39.55%+134.77%TBPHTheravance Biopharma-0.54%-3.68%+4.68%-7.47%-18.05%TYRATyra Biosciences-2.32%+10.73%-2.85%+19.85%+27.69%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin1.3341 of 5 stars2.94.00.00.01.90.00.6DYNDyne Therapeutics3.2112 of 5 stars4.61.00.00.01.24.20.6TBPHTheravance Biopharma2.1168 of 5 stars3.52.00.00.01.72.50.6TYRATyra Biosciences0.759 of 5 stars3.30.00.00.00.03.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin1.75Reduce$1.0825.95% UpsideDYNDyne Therapeutics3.14Buy$37.4357.96% UpsideTBPHTheravance Biopharma3.00Buy$20.50124.29% UpsideTYRATyra Biosciences2.67Moderate Buy$22.0045.60% UpsideCurrent Analyst RatingsLatest TYRA, TBPH, DYN, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/26/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/21/2024TYRATyra BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$28.003/20/2024TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $23.003/8/2024DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $31.003/6/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.003/6/2024DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $41.003/6/2024DYNDyne TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $29.003/5/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$44.00 ➝ $47.002/20/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$306.91M1.15N/AN/A$1.35 per share0.64DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ATBPHTheravance Biopharma$57.42M7.73N/AN/A$4.28 per share2.14TYRATyra BiosciencesN/AN/AN/AN/A$4.74 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$0.14N/AN/AN/A-19.26%-10.47%-6.97%5/1/2024 (Confirmed)DYNDyne Therapeutics-$235.94M-$3.94N/AN/AN/AN/A-136.35%-103.67%5/9/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)TYRATyra Biosciences-$69.13M-$1.61N/AN/AN/AN/A-30.26%-28.53%5/2/2024 (Estimated)Latest TYRA, TBPH, DYN, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AAMRNAmarin-$0.0350N/A+$0.0350N/AN/AN/A 3/19/2024Q4 2023TYRATyra Biosciences-$0.48-$0.53-$0.05-$0.53N/AN/A3/5/202412/31/2023DYNDyne Therapeutics-$0.92-$1.09-$0.17-$1.09N/AN/A2/29/2024Q4 2023AMRNAmarin-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 million2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A2.801.80DYNDyne TherapeuticsN/A2.532.53TBPHTheravance BiopharmaN/A5.395.39TYRATyra BiosciencesN/A13.8113.80OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%DYNDyne Therapeutics96.68%TBPHTheravance Biopharma99.10%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%DYNDyne Therapeutics20.77%TBPHTheravance Biopharma6.90%TYRATyra Biosciences18.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin275410.67 million402.62 millionOptionableDYNDyne Therapeutics14186.18 million68.28 millionOptionableTBPHTheravance Biopharma35948.56 million45.21 millionOptionableTYRATyra Biosciences4952.52 million42.86 millionOptionableTYRA, TBPH, DYN, and AMRN HeadlinesSourceHeadlineTyra Biosciences (NASDAQ:TYRA) Shares Down 7.3% marketbeat.com - April 25 at 7:46 PMTyra Biosciences (NASDAQ:TYRA) Stock Price Down 8.3%marketbeat.com - April 10 at 3:24 PMTyra Biosciences (NASDAQ:TYRA) Shares Gap Up to $16.15marketbeat.com - March 27 at 11:47 AMTyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug Developmentmarkets.businessinsider.com - March 26 at 2:16 PMTYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023msn.com - March 19 at 10:35 PMTyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progressfinance.yahoo.com - March 19 at 10:35 PMTyra Biosciences files to sell 15.37M shares of common stock for holdersmsn.com - March 19 at 5:35 PMTyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlightsfinance.yahoo.com - March 19 at 5:35 PMTyra Biosciences, Inc. (NASDAQ:TYRA) COO Daniel Bensen Sells 1,733 Sharesinsidertrades.com - March 18 at 6:48 AMInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Sharesfinance.yahoo.com - March 6 at 6:14 PMInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Sharesfinance.yahoo.com - March 1 at 8:49 AMTyra Biosciences to Present at Upcoming Investor Conferencesprnewswire.com - February 27 at 4:05 PMTyra Biosciences (TYRA) Price Target Increased by 5.41% to 23.87msn.com - February 24 at 9:56 AMTYRA Mar 2024 20.000 callfinance.yahoo.com - February 17 at 8:33 AMTYRA Mar 2024 20.000 putfinance.yahoo.com - February 17 at 8:33 AMTyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 7 at 7:02 PMPresident and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA)finance.yahoo.com - February 7 at 2:01 PMTyra Bioscience Announces New Purchase Agreementmsn.com - February 6 at 5:58 PMTyra Bioscience Secures $200M for Clinical Drug Developmentmsn.com - February 6 at 7:56 AMUS FDA grants rare paediatric disease designation to Tyra Biosciences’ TYRA-300 to treat achondroplasiapharmabiz.com - February 3 at 9:42 AMTYRA-300 designated rare pediatric disease drug; Tyra collects $200Mbioworld.com - February 2 at 7:06 PMTyra Bioscienes Scores $200M In PIPEsocaltech.com - February 2 at 2:06 PMTyra Biosciences Climbs 23% After Announcing $200 Mln Private Placementnasdaq.com - February 2 at 2:06 PMTyra Shares Jump After $200 Million Private Placement Fundingmarketwatch.com - February 2 at 2:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeNucor Stock Earnings Riding the Steel Industry WaveApril 25, 2024 7:25 AMView Nucor Stock Earnings Riding the Steel Industry WaveAll Headlines Company DescriptionsAmarinNASDAQ:AMRNAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Dyne TherapeuticsNASDAQ:DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Tyra BiosciencesNASDAQ:TYRATyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.